跳至主要内容
临床试验/NCT03025945
NCT03025945已完成不适用

Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Intuor Technologies, Inc.0 个研究点目标入组 662 人开始时间: 2013年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
662
主要终点
Post-operative Clinical Findings of Cystoid Macular Edema

研究概览

简要总结

Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects, 18 and older subjects with visually significant cataracts and were to undergo phacoemulsification with implantation of an intracapsular positioned intraocular lens.

排除标准

  • previous uveitis (<1 year) previous anterior segment intraocular surgery hypersensitivity or allergy to NSAIDs

研究组 & 干预措施

Saline Solution

Placebo Comparator

sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily

干预措施: Saline Solution (Drug)

nepafenac 0.3%

Experimental

nepafenac 0.3% ophthalmic solution dosed once daily

干预措施: Nepafenac 0.3% (Drug)

结局指标

主要结局

Post-operative Clinical Findings of Cystoid Macular Edema

时间窗: 6 weeks

post-operative macular volume (mm)

次要结局

未报告次要终点

研究者

发起方
Intuor Technologies, Inc.
申办方类型
Industry
责任方
Sponsor

相似试验